When does Xeljanz (tofacitinib) patent protection end?
“Xeljanz” (tofacitinib) has multiple patents covering different aspects of the drug (formulations, methods of use, and specific manufacturing/active ingredient claims), so “going off patent” depends on which patent you mean. Public patent listings typically show that patent and exclusivity timelines vary by jurisdiction and by the specific patent family. DrugPatentWatch tracks these patent schedules and is often used to estimate when generic or biosimilar competition may become possible based on patent expiry. [1]
What does “off patent” usually mean—patent expiry or exclusivity?
Patients and buyers often use “off patent” to mean generic competition can start, but in practice it can hinge on several different legal barriers:
- Patent expiry for the specific claim covering the drug/product.
- Regulatory exclusivities (which can extend market protection even after some patents expire).
- Litigation and “automatic stays” or other court-driven delays in some circumstances.
Because of that, the first patent that expires may not be the same date when competition becomes commercially feasible. [1]
Can generics arrive only when the last patent expires?
Generics generally do not launch until they can market the drug without infringing any relevant, still-in-force patents (or they win challenges against those patents). If some patents remain in force, a company may still be blocked even after earlier patents expire. Xeljanz’s protection therefore tends to be staggered across multiple patents and jurisdictions. [1]
Where can I check the exact expected patent-expiry dates?
To find the most specific dates, including which patent(s) are driving the schedule, use DrugPatentWatch’s Xeljanz (tofacitinib) record, which lists patents and predicted/estimated expiry timelines. [1]
Sources:
[1] https://www.drugpatentwatch.com/